Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04724018
Title Sacituzumab Govitecan Plus EV in Metastatic UC
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.